POLIVY plus a chemotherapy regimen of bendamustine and a rituximab product (POLIVY+BR) was compared with BR by itself in a clinical trial.

POLIVY was studied in 80 patients with R/R DLBCL

The people in the study were randomly placed into 2 separate treatment groups

Patients received either POLIVY+BR or BR by itself every 21 days for 6 treatment cycles. Both patients and healthcare providers knew which treatment had been given.

In order to see how POLIVY works, patients in the study were also sorted by the length of time they responded to a previous treatment (also known as duration of response, or DoR).

The study included patients with R/R DLBCL who:

  • Had already received at least one prior treatment for their DLBCL
  • Were not candidates for a type of stem cell transplantation called HSCT
  • Were 30 to 86 years old (average age 69 years)

The study did not include people who had:

  • A history of moderate to severe nerve problems in their arms or legs
  • Prior treatment with certain types of stem cell transplantation
  • Central nervous system lymphoma* or transformed lymphoma

HSCT=hematopoietic stem cell transplantation.
*Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which cancer cells from other parts of the body form in the brain and/or spinal cord.
Transformed lymphoma occurs when a slow-growing lymphoma develops into a more aggressive one.

Please talk to your doctor about whether POLIVY is right for you

Results in R/R DLBCL

POLIVY™ (polatuzumab vedotin-piiq) effectiveness icon - see the efficacy results of POLIVY+BR

See the efficacy results of POLIVY+BR

How Does POLIVY Work?

POLIVY™ (polatuzumab vedotin-piiq) icon for how it may work

Learn about how POLIVY was designed to treat R/R DLBCL

The Infusion Process

POLIVY™ (polatuzumab vedotin-piiq) icon for infusion process

See the infusion process and dosing schedule for POLIVY+BR